ALPINE GROUP PARTNERS, LLC.
Lobbying for EMERGENT BIOSOLUTIONS · Specialty Pharmaceutical Company
Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY26 Opioid crisis legislation, naloxone access and awareness State opioid response (SOR) Grant funding FY26 Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY26 Tribal Opioid Response Grant funding for FY26 NDAA for Fiscal Year 2025 and Fiscal Year 2026 - provisions related to biological and chemical defense and access to naloxone H.R. 1968, the Full-Year Continuing Appropriations and Extensions Act, 2025 H.R. 2483, SUPPORT for Patients and Communities Reauthorization Act of 2025 H.R. 5252, HOPE Act
Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY26 Opioid crisis legislation, naloxone access and awareness State opioid response (SOR) Grant funding FY26 Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY26 Tribal Opioid Response Grant funding for FY26 NDAA for Fiscal Year 2025 and Fiscal Year 2026 - provisions related to biological and chemical defense and access to naloxone H.R. 1968, the Full-Year Continuing Appropriations and Extensions Act, 2025 H.R. 2483, SUPPORT for Patients and Communities Reauthorization Act of 2025 H.R. 5252, HOPE Act